REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

N/ANot Yet RecruitingNCT07346547

Nabiqasim Industries (Pvt) Ltd384 enrolled

Overview

A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat

Study Type

OBSERVATIONAL

Enrollment

384

Conditions

CKD Anemia

Interventions

DaprodustatDRUG

Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR) * Patients on hemodialysis (HD) or peritoneal dialysis (PD) * Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent Exclusion Criteria 1. Acute Kidney Injury (AKI) without underlying chronicity 2. Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia) 3. Refusal or inability to provide consent 4. Current enrollment in an interventional trial that restricts real-world data collection 5. Life expectancy \< 3 months, where follow-up is not feasible 6. Known contraindications to Daprodustat as per local prescribing information

Outcomes

Primary Outcomes

Serum hemoglobin levels

Hemoglobin response to therapy

Time frame: 3 months

Secondary Outcomes

Frequency of MACE ( Major Adverse Cardiovascular Events)

MACE events: * Unstable angina requiring hospitalization * Non-fatal MI * Non-fatal stroke * Cardiovascular death * Other adverse events * Hospitalization episodes . Mortality * Optional patient-reported outcomes (fatigue, functional status)

Time frame: 3 months

Central Contacts

Hussain Abidi

CONTACT

+923322583236 NQmedicalaffairs@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.